CLX

Business profile & competitive position

The Clorox Company operates in the Consumer Defensive sector, specifically the Household & Personal Products industry. Its portfolio spans bleach and cleaning brands, water-filtration, charcoal, trash bags, cat litter, personal care, and health and wellness products. That mix makes it a classic staples business: demand for disinfectants, cleaning supplies, and everyday household goods stays relatively steady across economic cycles.

The company’s reported net margin is 8.7%, which sits below many premium consumer-defensive peers but is consistent with a business whose categories carry heavy marketing and commodity-related input costs. More striking is the ROE of -1893.5%. A negative ROE at that magnitude typically signals a deficit or very low shareholder equity rather than an operating loss, often after debt-funded buybacks, goodwill write-downs, or balance-sheet restructuring. Whatever the precise accounting driver, the figure implies equity is thin relative to earnings, so the conventional “return on equity competitive moat” signal is inverted here. A healthy moat would usually show stable double-digit margins and positive, consistent ROE; Clorox’s margin is mid-single-digit in net terms and its capital structure has produced an extreme negative equity position. Investors should therefore interpret “moat” cautiously: brand recognition may buffer volume, but the balance sheet does not currently reflect strong capital efficiency.

Financial posture

Clorox carries a market capitalization of $12.7 billion and trades at a trailing P/E of 21.8. That valuation is lower than many high-growth consumer names, but it is not cheap by historical staples standards. The 8.7% net margin supports steady cash generation but does not leave a wide margin for error, especially if costs rise.

The beta of 0.53 confirms the stock behaves less volatile than the broad market, matching the defensive label. Nevertheless, the -1893.5% ROE and any accompanying leverage mean the business is financially engineered in ways the beta figure alone does not capture. P/E compression is already priced in relative to peak multiples, yet 21.8x still requires earnings stability to avoid further derating. Overall, Clorox looks like a reasonably valued, low-beta staples stock with a capital structure that skews riskier than the sector average.

Macro & geopolitical exposure

As a Household & Personal Products company, Clorox is exposed to the macro themes that normally affect consumer staples. Input cost inflation for chemicals, plastics, fiber, resin, and transportation directly pressures gross margins. Tariff and trade policy can raise the cost of imported components or finished goods, while currency swings affect the translation of international sales. Regulatory scrutiny of household chemicals, disinfectant labeling, and environmental packaging is also an ongoing risk in this industry.

Because the sector is non-discretionary, volume demand usually holds up during recessions, but pricing power is not unlimited. Persistent inflation can push consumers toward private-label alternatives or smaller pack sizes, pressuring both volume and mix. Supply-chain disruptions can shelf-availability quicker for high-frequency items, and labor costs in manufacturing and distribution matter more here than in asset-light businesses. Interest rates matter too: a leveraged balance sheet raises debt-servicing costs and reduces financial flexibility compared with less geared peers.

Recent developments

The most recent news cluster centers on Clorox’s fiscal fourth-quarter results reported on August 4, 2026. Zacks noted that Q4 earnings and sales topped estimates, with GOJO supporting sales. In a separate article the same day, Zacks’ Q4 earnings call coverage flagged inflation as a headwind while saying share recovery is building. Also on August 4, 2026, Benzinga reported that several analysts raised their forecasts after the better-than-expected Q4 outcome. A week later, on August 6, 2026, Zacks published a value comparison, “NWL vs. CLX: Which Stock Is the Better Value Option?”

These headlines together paint a consistent picture: near-term results beat expectations and the GOJO acquisition is contributing topline momentum, but management’s commentary still emphasizes inflationary pressure. The analyst forecast upgrades show the Q4 beat was not simply ignored, yet the repeated inflation reference suggests margin recovery remains a work in progress rather than a settled story.

Earnings behavior & post-earnings drift

Clorox has beaten estimates in 6 of the last 8 reported quarters, a 75% beat rate, with an average earnings surprise of 9.4%. Despite that solid headline record, the average 5-day post-earnings move across those quarters is -0.98%, classified as a negative drift. That divergence is important: beating the consensus has not reliably translated into follow-through buying.

The last four quarters illustrate the pattern. On August 3, 2026, CLX reported EPS of $1.66 against an estimate of $1.64, a 1.2% beat, and the stock rose 6.52% the next day but finished the following five sessions flat at 0%. On April 30, 2026, the company beat by 5.8% with actual EPS of $1.64 versus $1.55, yet the stock fell 9.67% the next day and drifted down another 4.49% over the next five sessions. The February 3, 2026 quarter was a miss—$1.39 actual against $1.43 estimate—but the stock still gained 2.43% the next day and rose 5.63% over the next five sessions. The November 3, 2025 quarter then delivered a 3.9% beat, producing only a 1.17% next-day move and a negative 5-day drift of -4.08%.

This means the market’s real expectation may not be captured by the published consensus alone. When results are modest beats, the stock can sell off because expectations were higher than estimates. When results miss, relief rallies can occur because the miss was already priced in. The next scheduled report is November 3, 2026 after the close, with a consensus EPS estimate of $1.07. That is a lower absolute EPS than recent quarters, reflecting normal seasonality, so the year-over-year and sequential comparisons—not only the beat or miss—will likely drive the price reaction.

For a deeper dive into whether the Q4 improvements are sustainable and where the analyst community stands after the recent estimate revisions, review the full institutional verdict on Clorox.